Coherus Oncology, Inc. (CHRS)
$1.07+3.88%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $131M
- Beta
- 0.99
- P/E (TTM)
- -1.05
- Short % float
- 20.13%
- Days to cover
- 12.5
- SI change
- +2.1%
- 1W
- +3.88%
- 1M
- -25.17%
- vs SPY 1W
- +4.02%
- vs SPY 1M
- -27.68%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 32
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-109.0%
REV YoY-
ROE-181.7%
EPS YoY-
ROA-68.5%
GROSS64
OP-307
NET-257
[VALUATION]
P/E TTM-1.05
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.72
P/FCF-
EV/EBITDA-0.81
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E61.98
ALTMAN Z-
CURR RATIO1.77
ND/EBITDA-
BETA0.99
Company news
FAQ
- What is LOPJLB’s current signal on CHRS?
- LOPJLB’s latest quantitative signal on Coherus Oncology, Inc. (CHRS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CHRS in?
- Coherus Oncology, Inc. (CHRS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Coherus Oncology, Inc. (CHRS) do?
- Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed …